271 related articles for article (PubMed ID: 27176573)
1. Botulinum toxin type B for cervical dystonia.
Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A therapy for cervical dystonia.
Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A therapy for blepharospasm.
Duarte GS; Rodrigues FB; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD004900. PubMed ID: 33211907
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A versus anticholinergics for cervical dystonia.
Rodrigues FB; Duarte GS; Castelão M; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD004312. PubMed ID: 33852744
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Costa J; Borges A; Espírito-Santo C; Ferreira J; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004314. PubMed ID: 15674940
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Deep brain stimulation for dystonia.
Rodrigues FB; Duarte GS; Prescott D; Ferreira J; Costa J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012405. PubMed ID: 30629283
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A therapy for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD003633. PubMed ID: 15674910
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Figgitt DP; Noble S
Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A versus anticholinergics for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004312. PubMed ID: 15674939
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A therapy for hemifacial spasm.
Duarte GS; Rodrigues FB; Castelão M; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD004899. PubMed ID: 33211908
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
17. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
18. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E; Ellis C; Brassington R; Sathasivam S; Young CA
Cochrane Database Syst Rev; 2022 May; 5(5):CD006981. PubMed ID: 35593746
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxins for the prevention of migraine in adults.
Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
